Trial Profile
Safety and Fibrosis Improvement of Grazoprevir and Elbasvir for HCV GT1 and GT6 With or Without HIV
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 13 May 2022
Price :
$35
*
At a glance
- Drugs Elbasvir (Primary) ; Grazoprevir (Primary) ; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- 17 Feb 2021 Primary endpoint (Rate of SVR12) has not been met, as per results published in the Journal of Infectious Diseases.
- 17 Feb 2021 Results assessing microbial patterns of HCV-monoinfected and HCV/HIV-coinfected patients differed significantly from those of healthy controls, published in the Journal of Infectious Diseases
- 11 Feb 2020 Planned End Date changed from 31 Aug 2019 to 31 Dec 2020.